Quantcast
Last updated on April 23, 2014 at 12:21 EDT

Latest Genzyme Stories

2014-01-09 08:26:53

- Industry Veterans Bring a Wealth of Commercial and Business Development Experience - CAMBRIDGE, Mass., Jan. 9, 2014 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced the appointment of Alicia Secor to the newly created position of Chief Commercial Officer, and the appointment of John L. LaMattina to the Company's Board of Directors. Ms. Secor joins Zafgen as an experienced health...

2014-01-08 12:28:46

SARASOTA, Fla., Jan. 8, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Geoffrey F. Cox, Ph.D., to serve on its board of directors. Dr. Cox, currently an independent consultant to the Biotechnology and Life Sciences Industry and Principal of Beacon Street Advisors, brings to the company significant experience of the biotechnology industry, through a number of positions as a Senior Executive...

2014-01-07 08:30:25

ST. LOUIS, Jan. 7, 2014 /PRNewswire/ -- ISTO Technologies, Inc., a privately-held orthobiological regenerative medicine company, announced today that James McGorry, a seasoned executive with deep healthcare industry experience, has been appointed to its Board of Directors. "We welcome Jim McGorry, whose expertise in the biotech industry and leadership experience with ground-breaking oncological and transplant therapies will help guide ISTO as we continue to develop and promote our...

2013-12-12 20:24:22

WAYNE, Pa., Dec. 12, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York on behalf of purchasers of Sanofi contingent value rights (NASDAQ: GCVRZ) ("CVRs" or "shares") between March 6, 2012 and November 7, 2013, inclusive (the "Class Period"). (Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO ) For more information regarding this class action suit,...

2013-12-04 08:30:49

CHERRY HILL, N.J., Dec. 4, 2013 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) announces a national call for entries for the Swim for MS - Why I Swim campaign, through a collaborative sponsorship with Genzyme, a Sanofi company. Individuals with multiple sclerosis (MS) who currently swim or participate in water-based exercise programs are encouraged to visit SwimForMS.org and share their personal story about how water activities have impacted their lives. Why I Swim is...

2013-12-02 08:30:54

DURHAM, N.C., Dec. 2, 2013 /PRNewswire/ -- Scioderm, Inc. announced the appointment of John Crowley and William Aliski to the company's Board of Directors. As Chairman & CEO of NASDAQ listed Amicus Therapeutics, John brings a significant rare and orphan disease experience to Scioderm, in addition to his in depth transactional and public sector market experience. His personal drive, commitment and overall determination to find cures for rare diseases such as Pompe and Fabry...

2013-11-25 12:27:25

More Neurologists Now Mention Once-Daily Dosing As Aubagio's Biggest Advantage Compared With Earlier in Launch, According to a New Report from BioTrends Research Group EXTON, Pa., Nov. 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds of surveyed U.S. neurologists have prescribed Genzyme's Aubagio, the second oral disease-modifying therapy (DMT) to reach the...

2013-11-20 08:28:20

MISSISSAUGA, ON, Nov. 20, 2013 /CNW/ - Genzyme, a Sanofi company, announced today that Health Canada has approved AUBAGIO® (teriflunomide) 14 mg as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. "There are many patients who simply cannot tolerate injections and have had no simple, effective, once daily oral medication until now,"...

2013-11-14 23:04:03

Reportbuyer.com just published a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules. London (PRWEB) November 14, 2013 The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen’s Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera’s launch in Europe. Genzyme have taken advantage of...

2013-10-30 08:30:54

Proceeds to Advance Multiple Next-Generation Cancer Immunotherapy Product Candidates SEATTLE and SAN FRANCISCO, Oct. 30, 2013 /PRNewswire/ -- Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million. This Series C round includes an upfront investment of $32.5 million, with the right of the syndicate to invest an additional $16.5...